Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticlePerspective

Contribution of Metabolites to P450 Inhibition-Based Drug-Drug Interactions: Scholarship from the IQ DMLG Metabolite Group

Hongbin Yu, Suresh K. Balani, Weichao Chen, Donghui Cui, Ling He, William Griffith Humphreys, Jialin Mao, W. George Lai, Anthony J. Lee, Heng-Keang Lim, Christopher MacLauchlin, Chandra Prakash, Sekhar Surapaneni, Susanna Tse, Alana Upthagrove, Robert L. Walsky, Bo Wen and Zhaopie Zeng
Drug Metabolism and Disposition February 5, 2015, dmd.114.059345; DOI: https://doi.org/10.1124/dmd.114.059345
Hongbin Yu
1 Boehringer Ingelheim Pharmaceuticals. Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hongbin.yu@boehringer-ingelheim.com
Suresh K. Balani
2 Takeda Pharmaceuticals International Co.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weichao Chen
3 Vertex Pharmaceuticals;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donghui Cui
4 Merck Research Laboratories;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling He
5 Daiichi Sankyo, Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Griffith Humphreys
6 Bristol-Myers-Squibb;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jialin Mao
7 Genentech;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. George Lai
8 Eisai Pharmaceuticals;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony J. Lee
9 Abbivie;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heng-Keang Lim
10 Janssen Research and Development;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher MacLauchlin
11 GlaxoSmithKline;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandra Prakash
12 Biogen Idec;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sekhar Surapaneni
13 Celgene Corporation;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna Tse
14 Pfizer Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alana Upthagrove
15 Novartis Pharmaceuticals Corporation;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. Walsky
16 EMD Serono Research Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Wen
11 GlaxoSmithKline;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaopie Zeng
17 Sanofi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Next
Back to top

In this issue

Drug Metabolism and Disposition: 49 (3)
Drug Metabolism and Disposition
Vol. 49, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Contribution of Metabolites to P450 Inhibition-Based Drug-Drug Interactions: Scholarship from the IQ DMLG Metabolite Group
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticlePerspective

Contribution of Metabolites to P450 Inhibition-Based Drug-Drug Interactions: Scholarship from the IQ DMLG Metabolite Group

Hongbin Yu, Suresh K. Balani, Weichao Chen, Donghui Cui, Ling He, William Griffith Humphreys, Jialin Mao, W. George Lai, Anthony J. Lee, Heng-Keang Lim, Christopher MacLauchlin, Chandra Prakash, Sekhar Surapaneni, Susanna Tse, Alana Upthagrove, Robert L. Walsky, Bo Wen and Zhaopie Zeng
Drug Metabolism and Disposition February 5, 2015, dmd.114.059345; DOI: https://doi.org/10.1124/dmd.114.059345

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticlePerspective

Contribution of Metabolites to P450 Inhibition-Based Drug-Drug Interactions: Scholarship from the IQ DMLG Metabolite Group

Hongbin Yu, Suresh K. Balani, Weichao Chen, Donghui Cui, Ling He, William Griffith Humphreys, Jialin Mao, W. George Lai, Anthony J. Lee, Heng-Keang Lim, Christopher MacLauchlin, Chandra Prakash, Sekhar Surapaneni, Susanna Tse, Alana Upthagrove, Robert L. Walsky, Bo Wen and Zhaopie Zeng
Drug Metabolism and Disposition February 5, 2015, dmd.114.059345; DOI: https://doi.org/10.1124/dmd.114.059345
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Regulatory Guidance for P450 Induction from IQ: Part 3
  • Prioritizing NPs as precipitants of NPDIs
  • Regulatory Guidance for P450 Induction from IQ
Show more Perspective

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics